Capecitabine and docetaxel combination for the treatment of breast cancer

Women's Health

Volumn 4, Issue 1, 2008, Pages 11-22

  Morishita, Mariko ^a   Leonard, Robert C ^a,b  

^a IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

^b IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

Breast cancer; Capecitabine; Docetaxel; Taxanes

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; CAPECITABINE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; FLUOROPYRIMIDINE DERIVATIVE; GEMCITABINE; NAVELBINE; PACLITAXEL; TAXANE DERIVATIVE; THYMIDINE PHOSPHORYLASE; TRASTUZUMAB;

ADJUVANT THERAPY; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BACKACHE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BREAST CANCER; BURNING SENSATION; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DISEASE COURSE; DISEASE SEVERITY; DOSE CALCULATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG POTENTIATION; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; GASTROINTESTINAL SYMPTOM; HAND FOOT SYNDROME; HEALTH CARE COST; HUMAN; LEUKOPENIA; LOADING DRUG DOSE; METASTASIS; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MYALGIA; NEUROPATHY; NEUTROPENIA; NONHUMAN; PAIN; PATIENT COMPLIANCE; QUALITY OF LIFE; SEPSIS; SIDE EFFECT; SINGLE DRUG DOSE; SKIN TINGLING; SKIN TOXICITY; SURVIVAL TIME; TREATMENT DURATION; UPREGULATION;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; COST-BENEFIT ANALYSIS; DEOXYCYTIDINE; FEMALE; FLUOROURACIL; HUMANS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TAXOIDS;

EID: 38049174663     PISSN: 17455057     EISSN: 17455065     Source Type: Journal    
DOI: 10.2217/17455057.4.1.11     Document Type: Article

References (65)

1. Spielmann M, Tubiana-Hulin M, Namer M et al.: Sequential or alternating administration of docetaxel (Taxotere) combined with FEC in metastatic breast cancer: a randomised Phase II trial. Br. J. Cancer 86, 692-697 (2002).
2. Sledge GW, Neuberg D, Bernardo P et al.: Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxil as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193). J. Clin. Oncol. 21, 588-592 (2003).
3. Nabholtz JM, Falkson C, Campos D et al.: Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, Phase III trial. J Clin. Oncol. 21, 968-975 (2003).
4. Bontenbal M, Creemers GJ, Braun HJ et al.: Dutch Community Setting Trial for the Clinical Trial Group. Phase II to III study comparing doxorubicin and docetaxel with fluorouracil, doxorubicin, and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer: results of a Dutch Community Setting Trial for the Clinical Trial Group of the Comprehensive cancer Centre. J. Clin. Oncol. 23, 7081-7088 (2005).
5. Langley RE, Carmichael J, Jones AL et al.: Phase III trial of epirubicin plus pactitaxel compared with epirubicin plus cyclophosphamide as first-line chemotherapy for metastatic breast cancer: United Kingdom National Cancer Research Institute trial AB01. J. Clin. Oncoi. 23, 8322-8330 (2005).
6. Nabholtz JM, Mackey JR, Smylie M et al.: Phase II study of docetaxel, doxorubicin, and cyclophosphamide as first-line chemotherapy for metastatic breast cancer. J. Clin. Oncol. 19(2), 314-321 (2001).
7. Matinovszky K, Johnston S, Barrett-Lee P et al.: TEXAS (Taxotere® EXperience with Anthracyclines Study) trial: mature results of activity/ toxicity of docetaxel given with anthracyclines in a community setting, as first line therapy for MBC. Cancer Chemother. Pharmacol. 59(3), 413-418 (2007).
8. Roche H, Fumoleau P Spielmann M et al.: Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial. J. Clin. Oncol. 24, 5664-5671 (2006).
9. Martin M, Lluch A, Segui MA et al.: Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylacticgranulocyte-colony stimulating factor to the TAC regimen. Ann. Oncol. 17, 1205-1212 (2006).
10. Blum JL, Jones SE, Buzdar AU et al.: Multicenter Phase II study of capecitabine in paclitaxel-reftactory metastatic breast cancer. J. Clin. Oncol. 17, 485-493 (1999).
11. Blum JL, Dieras V, Lo Russo PM et al.: Multicenter, Phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients. Cancer92, 1759-1768 (2001).
12. Reichardt P, Von Minckwitz G, Thuss-Patience PC et al.: Multicenter Phase II study of oral capecitabine (Xeloda®) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy. Ann. Oncol. 14, 1227-1233 (2003).
13. Fumoleau P, Largillier R, Clippe C et al.: Multicentre, Phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer. Eur. J. Cancer. 40, 536-542 (2004).
14. O'Shaughnessy J, Miles D, Vukelja S et al.: Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pre-treated patients with advanced breast cancer: Phase III trial results. J Clin. Oncol. 20, 2812-2823 (2002).
15. Twelves C, Fumoleau P, Jones SE et al.: Adding Xeloda® (capecitabine) to docetaxel significantly improves survival and does not compromise quality of life in patients with metastatic breast cancer. Breast Cancer Res. Treat. 69, 307 (2001) (Abstract 542).
16. Verma S, Maraninchi D, O'Shaughnessy J et al.: Capecitabine plus docetaxel combination therapy. Cancer 103(12), 2455-2465 (2005).
17. Priol G, Maurel F, le Pen C: Cost-effectiveness analysis of capecitabine in combination with docetaxel in comparison to clocetaxel monotherapy in advanced or metastatic breast cancer in France. Bull. Cancer92(9), 809-816 (2005).
18. Verma S, Itersich A: Population-based phamacoeconomic model for adopting capecitabine/docetaxel combination treatment for anthracycline-pretreated metastatic breast cancer. Onoclogist 8, 232-240 (2006).
19. Miwa M, Ura M, Nishida M et al.: Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur. J. Cancer. 34(8), 1274-1281 (1998).
20. Schuller J, Cassidy J, Dumont E et al.: Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother Pharmacol. 45(4), 291-297 (2000).
21. Sawada N, Ishikawa T, Fukase Y et al.: Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by Taxol/ Taxotere in human cancer xenografts. Clin. Cancer Res. 4, 1013-1019 (1998).
22. Fujimoto-Ouchi K, Tanaka Y, Tominaga T Schedule dependency of antitumor activity in combination therapy with capecitabine/ 5′-deoxy-5-fluorouridine and docetaxel in breast cancer models. Clin. Cancer Res. 7, 1079-1086 (2001).
23. Mavroudis D, Ardavanis A, Boukovinas I et al.: A multicenter randomized study comparing vinorelbine plus gemcitabine versus capecitabine monotherapy as salvage treatment in patients with advanced breast cancer pretreated with taxane and anthracycline chemotherapy: a preliminary report. ASCO Annual Meeting Proceedings Part I. 24, S18 (2006) (Abstract 658).
24. Miller KD, Chap LI, Holmes FA et al.: Randomized Phase III trial of capecitabine compared with bevacizurnab plus capecitabine in patients with previously treated metastatic breast cancer. J. Clin. Oncol. 23(4), 792-799 (2005).
25. O'Shaughnessy JA, Blum J, Moiseyenko V et al.: Randomized, open-label, Phase II trial of oral capecitabine (Xeloda®) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-tine therapy for advanced/metastatic breast cancer. Ann. Oncol. 12, 1247-1254 (2001).
26. Talbot DC, Moiseyenko V, van Belle S et al.: Randomised, Phase II trial comparing oral capecitabine (Xeloda®) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines. Br. J. Cancer 86, 1367-1372 (2002).
27. Stockler M, Sourjina T, Grimison P et al.: ANZ Breast Cancer Trials Group: A randomized trial of capecitabine (C) given intermittently (IC) rather than continuously (CC) compared to classical CMF as first-line chemotherapy for advanced breast cancer (ABC). ASCO Annual Meeting Proceedings (2007) (Abstract 1031).
28. Paridaens R, Biganzoli L, Bruning P et al.: Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer randomized study with cross-over. J. Clin. Oncol. 18, 724-733 (2000).
29. Sjöström J, Blomqvist C, Mouridsen H et al.: Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomised Phase III study with crossover on progression by the Scandinavian Breast Group. Eur. J. Cancer. 35, 1194-1201 (1999).
30. Alexandre J, Bleuzen P, Bornneterre J et al.: Factors predicting for efficacy and safety of docetaxel in a compassionate-use cohort of 825 heavily pre-treated advanced breast cancer patients. J. Clin. Oncol. 18, 562-573 (2000).
31. Jones SE, Erban J, Overmoyer B et al.: Randomized Phase III study of docetaxel compared with paclitaxel with metastatic breast cancer. J. Clin. Oncol. 23, 5542-5551 (2005).
32. Nabholtz JM, Senn HJ, Bezwoda WR et al.: Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group. J Clin. Oncol. 17(5), 1413-1424 (1999).
33. Mousidsen H, Harvey V, Semigiazov V et al.: Phase III study of docetaxel 100 versus 75 versus 60mg/sqm as second line chemotherapy in advanced breast cancer. Breast Cancer Res. Treat. 76 (Suppl. 1), S88 (2002).
34. Miller KD, Wang M, Gralow, J et al.: A randomized Phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer: a trial coordinated by the Eastern Cooperative Oncology Group (E2100). Breast Cancer Res. Treat. 94, S6 (2005).
35. Nabholtz JM, Gelmon K, Bontenbal M et al.: Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. J. Clin. Oncol. 14, 1858-1867 (1996).
36. Dieras V, Marty M, Tubiana N et al.: Phase II randomized study of paclitaxel versus mitomycin in advanced breast cancer. Semin. Oncol. 22(Suppl. 8), 33-39 (1995).
37. Tosello C, Segalla JGM, Ribeiro R et al.: Improvements in quality of life (QoL) associated with capecitabine (X) treatment for metastatic breast cancer (MBC) in Brazil: updated results from a large cohort of 1683 patients (pts), including analysis as a function of ECOG PS. San Antonio Breast Cancer Symposium (2006) (Abstract 5073).
38. Miles D, Vukelja S, Moiseyenko, V et al.: Survival benefit with capecitabine/docetaxel versus docetaxel alone: analysis of therapy in a randomized Phase III trial. Clin. Breast Cancer 5 (4), 273-278 (2004).
39. Leonard R, O'Shaughnessy J, Vukelja S et al.: Detailed analysis of a randomized Phase III trial: can the tolerability of capecitabine plus docetaxel be improved without compromising its survival advantage? Ann. Oncol. 17(9), 1379-1385 (2006).
40. Leonard R, Miles D, Reichardt P et al.: Optimizing the management of HER2-negative metastatic breast cancer with capecitabine (Xeloda®). Semin. Oncol. 31(Suppl. 10), 21-28 (2004).
41. Soto C, Torrecillas L, Reyes S et al.: Capecitabine (X) and taxanes in patients (pts) with anthracycline-pretreated metastatic breast cancer (MBC): sequential vs. combined therapy results from a MOSG randomized Phase III trial. Proc. Am. Soc. Clin. Oncol. 24 (18s) (2006) (Abstract 570).
42. Lebowitz PF, Eng-Wong J, Swain SM et al.: A Phase II trial of neoadjuvant docetaxel and capecitabine for locally advanced breast cancer. Clin, Cancer Res. 10, 6764-6769 (2004).
43. Roché H, Deporte R, Berton-Rigaud D et al.: Capecitabine + epirubicin + cyclophosphamide (CEX) has comparable safety to 5-FU + epirubicin + cyclophosphamide (FEC) as neoadjuvant therapy in patients (pts) with operable breast cancer (BC): early safety findings from a randomized Phase III trial. Proc. Am. Soc. Clin. Oncol. 24, S18 (2007) (Abstract 10655).
44. Gerbrecht BM, Kangas T. Implications of capecitabine (Xeloda) for cancer nursing practice. Eur. J. Oncol. Nurs. 8 (Suppl. 1), S63-S71 (2004).
45. Chau I, Legge S, Fumoleau P: The vital role of education and information in patients receiving capecitabine (Xeloda). Eur. J. Oncol. Nurs. 8(Suppl. 1), S41-53 (2004).
46. Lueck H, Minckwitz GV, du Bois A et al.: Epirubicin/paclitaxel (EP) vs. capecitabine/paclitaxel (XP) in first-line metastatic breast cancer (MBC): A prospective, randomized multicentre Phase III study of the AGO breast cancer study group. Proc. Am. Soc. Clin. Oncol. 24, S18 (2006) (Abstract 517).
47. Beslija S, Obralic N, Basic H et al.: Randomized trial of sequence vs. combination of capecitabine (X) and docetaxel (T): XT vs. T followed by X after progression as first-line therapy for patients (pts) with metastatic breast cancer (MBC). Proc. Am. Soc. Clin. Oncol. 24, S18 (2006) (Abstract 571).
48. Blum JL, Dees EC, Chacko A et al.: Phase II trial of capecitabine and weekly pactitaxel as first-line therapy for metastatic breast cancer. J. Clin. Oncol. 24(27), 4384-4390 (2006).
49. Somer BG, Schwartzberg LS, Arena F, Epperson A, Fu D, Fortner BV: Phase II trial of nab-paclitaxel (nanoparticle albumin-bound paclitaxel (ABX) + capecitabine (XEL) in first-line treatment of metastatic breast cancer (MBC). ASCO Annual Meeting Proceedings Part I. 25, S18 (2007) (Abstract 1053).
50. Bartsch R, Wenzel C, Altorjai G et al.: Capecitabine and trastuzumab in heavily pretreated metastatic breast cancer. J. Clin. Oncol. 25(25), 3853-3858 (2007).
51. Yamamoto D, Iwase S, Kitamura K, Odagiri H, Yamamoto C, Nagumo Y. A Phase II study of trastuzumab and capecitabine for patients with HER2-overexpressing metastatic breast cancer: Japan Breast Cancer Research Network (JBCRN) 00 Trial. Cancer Chemother. Pharmacol. (2007) (Epub ahead of print).
52. Schaller G, Fuchs I, Gonsch T et al.: Phase II study of capecitabine plus trastuzumab in human epidermal growth factor receptor 2 overexpressing metastatic breast cancer pretreated with anthracyclines or taxanes. J. Clin. Oncol. 25(22), 3246-3250 (2007).
53. Xu L, Song S, Zhu J et al.: Capecitabine (X) + trastuzumab (H) as first-line treatment in patients (pts) with HER2-positive metastatic breast cancer (MBC): Phase II trial results. San Antonio Breast Cancer Symposium (2006) (Abstract 2065).
54. Wardley A, Antón-Torres A, Pivot X et al.: Trastuzumab plus docetaxel with or without capecitabine in patients with HER2-positive advanced/metastatic breast cancer: first efficacy mutts from the Phase II MO16419 (CHAT) study. San Antonio Breast Cancer Symposium (2006) (Abstract 2063).
55. Bellet M, Muñoz M, Bellosillo, B et al.: Phase II study of capecitabine (X) + docetaxel M as neoadjuvant treatment in patients (pts) with locally advanced breast cancer (LABC) including biological correlates. Proc. Am. Soc. Clin. Oncol. 24, S18 (2006) (Abstract 664).
56. Lybaert W, Wildiers H, Neven P et al.: Docetaxel (T) + capecitabine (X) with or without trastuzumab (H) neoadjuvant therapy for locally advanced breast cancer (BC): Phase II study. Proc. Am. Soc. Clin. Oncol. 25, S18 (2007) (Abstract 11042).
57. Franco SX, Perez A, Tan-Chiu et al.: Updated results of a multicenter Phase II trial of neoadjuvant docetaxel, carboplatin and capecitabine for inflammatory and locally advanced breast cancer (LABC). J. Clin. Oncol. 24(18s) (2006) (Abstract 10685).
58. Lu YS, Kuo SH, Su WP et al.: A Phase II trial of docetaxel, capecitabine, and cisplatin as neoadjuvant chemotherapy for locally advanced breast cancer. Proc. Am. Soc. Clin. Oncol. 23, S16 (2005) (Abstract 861).
59. Perez-Manga G, Mendez M, Palomero MI et al.: Phase II study of neoadjuvant docetaxel (T), doxorubicin (A) and capecitabine (X) in locally advanced or inflammatory breast cancer. J. Clin. Oncol. 25(S18), 11092 (2007).
60. Lybaert W, Wildiers H, Neven P et al.: Multicenter Phase II study of neoadjuvant capecitabine (X), docetaxel (T) ± trastuzumab (H) for patients (pts) with locally advanced breast cancer (LABC): preliminary safety and efficacy data. Breast Cancer Res. Treat. (2006) (Abstract 3070).
61. Lee KS, Ro J, Nam B-H et al.: A randomized Phase III trial of docetaxel/capecitabine versus doxorubicin/cyclophosphamide as primary chemotherapy for patients with stage II/III breast cancer). Breast Cancer Res. Treat. (2007) (Epub ahead of print).
62. Steger GG, Greil R, Samonigg H et al.: An interim safety analysis of ABCSG-24: 6 cycles of docetaxel, epirubicin, and capecitabine + pegfilgrastim (DEC) vs. 6 cycles of docetaxel and epirubicin + pegfilgrastim (DE) in the neoadjuvant treatment of operable breast cancer. Breast Cancer Res. Treat. (2006) (Abstract 3097).
63. Von Minckwitz G, Rezai M, Loibl S et al.: First interim safety analysis of a Phase III trial exploring the efficacy of capecitabine and trastuzumab given concomitantly or in sequence to EC-Doc as neoadjuvant treatment of primary breast cancer. ASCO Beast Cancer Symposium. (2007) (Abstract 222).
64. Chan S, Romieu G, Huober J et al.: Gemcitabine plus docetaxel (GD) versus capecitabine plus docetaxel (CD) for anthracycline-pretreated metastatic breast cancer (MBC) patients (pts): results of a European Phase III study. Proc. Am. Soc. Clin. Oncol. 23, S16 (2005) (Abstract 581).
65. Fumoleau P, Romieu G, Chan S et al.: Impact of symptoms and toxicity on quality of life: exploratory analysis of gemcitabine plus docetaxel vs capecitabine plus docetaxel in metastatic breast cancer. Proc. Am. Soc. Clin. Oncol. 24, S18 (2006) (Abstract 682).